ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS (ANRE)

Clinical trials for ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS (ANRE) explained in plain language.

Never miss a new study

Get alerted when new ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS (ANRE) trials appear

Sign up with your email to follow new studies for ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS (ANRE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug aims to calm brain inflammation in rare autoimmune disease

Disease control Not yet recruiting

This early study tests a new medicine, ART5803, in 30 adults with Anti-NMDAR encephalitis (brain inflammation) or related psychiatric disease caused by the same antibodies. The main goals are to check if the drug is safe and tolerable, and to see early signs it might help control…

Matched conditions: ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS (ANRE)

Phase: PHASE2 • Sponsor: Arialys Australia Pty Ltd • Aim: Disease control

Last updated Apr 29, 2026 15:14 UTC

ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS (ANRE)

Get alerted when new ANTI-N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ENCEPHALITIS (ANRE) trials appear

New drug aims to calm brain inflammation in rare autoimmune disease